- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
Vitrolife
Market Cap: SEK 12.4b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 91.05
7D
0.1%
1Y
-34.4%
Egetis Therapeutics
Market Cap: SEK 3.2b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 7.33
7D
2.4%
1Y
41.0%
BioGaia
Market Cap: SEK 11.6b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 115.90
7D
2.6%
1Y
18.1%